Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted Building a commercial ecosystem to make it easier for women to discover, access and purchase products specifically designed for women Clinical pipeline continues to advance, led by positive interim Phase 3 Ovaprene® results and initiation of the DARE-HPV Phase 2 study Company to host conference call and webcast today, August 13, 2026, at 4:30 p.m. Eastern Time – Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE...
Source
Exhibit EX-99.1
0001493152-26-037737
Filed August 13, 2026 at 8:02 PM UTC. The figures above are from the audited statements, not from this release.